Matthew V Lorenzi
Overview
Explore the profile of Matthew V Lorenzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1653
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obermajer N, Zwolak A, van de Ven K, Versmissen S, Menard K, Rogers K, et al.
iScience
. 2025 Mar;
28(3):111876.
PMID: 40060890
T cell-redirecting bispecific antibodies (bsAbs) to treat advanced stage solid tumors are gaining interest after recent clinical successes. The immune checkpoint human leukocyte antigen G (HLA-G) is expressed in several...
2.
DeAngelis N, Ferrante C, Powers G, Sendecki J, Mattson B, Pizutti D, et al.
Cancer Chemother Pharmacol
. 2022 Mar;
89(4):515-527.
PMID: 35298699
Purpose: Preclinical characterization of cetrelimab (JNJ-63723283), a fully humanized immunoglobulin G4 kappa monoclonal antibody targeting programmed cell death protein-1 (PD-1), in human cancer models. Methods: Cetrelimab was generated by phage...
3.
Brahmer J, Johnson M, Cobo M, Viteri S, Coves Sarto J, Sukari A, et al.
JTO Clin Res Rep
. 2021 Sep;
2(2):100103.
PMID: 34589981
Introduction: JNJ-64041757 (JNJ-757) is a live, attenuated, double-deleted -based immunotherapy expressing human mesothelin. JNJ-757 was evaluated in patients with advanced NSCLC as monotherapy (phase 1) and in combination with nivolumab...
4.
Brehmer D, Beke L, Wu T, Millar H, Moy C, Sun W, et al.
Mol Cancer Ther
. 2021 Sep;
20(12):2317-2328.
PMID: 34583982
The protein arginine methyltransferase 5 (PRMT5) methylates a variety of proteins involved in splicing, multiple signal transduction pathways, epigenetic control of gene expression, and mechanisms leading to protein expression required...
5.
Vijayaraghavan S, Lipfert L, Chevalier K, Bushey B, Henley B, Lenhart R, et al.
Mol Cancer Ther
. 2020 Aug;
19(10):2044-2056.
PMID: 32747419
Small molecule inhibitors targeting mutant EGFR are standard of care in non-small cell lung cancer (NSCLC), but acquired resistance invariably develops through mutations in EGFR or through activation of compensatory...
6.
Yun J, Lee S, Kim S, Jeong S, Kim J, Pyo K, et al.
Cancer Discov
. 2020 May;
10(8):1194-1209.
PMID: 32414908
exon 20 insertion driver mutations (Exon20ins) in non-small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR-MET, has shown preclinical...
7.
Thompson J, Hwang W, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, et al.
Lung Cancer
. 2019 Nov;
139:1-8.
PMID: 31683225
Objectives: Treatment of non-small cell lung cancer (NSCLC) with immune checkpoint blockade (ICB) has resulted in striking clinical responses, but only in a subset of patients. The goal of this...
8.
Palakurthi S, Kuraguchi M, Zacharek S, Zudaire E, Huang W, Bonal D, et al.
Cancer Immunol Res
. 2019 Jul;
7(9):1457-1471.
PMID: 31331945
The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We hypothesized that combining targeted therapy...
9.
Zhang X, Wang J, Shao G, Wang Q, Qu X, Wang B, et al.
Nat Commun
. 2019 Apr;
10(1):1772.
PMID: 30992440
Deep understanding of the genomic and immunological differences between Chinese and Western lung cancer patients is of great importance for target therapy selection and development for Chinese patients. Here we...
10.
Curtin J, Lorenzi M
Oncotarget
. 2018 Nov;
9(78):34856.
PMID: 30410683
[This corrects the article DOI: 10.18632/oncotarget.191.].